This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yasojima, K. Articles by McGeer, P. L. Search for Related Content PubMed PubMed Citation Articles by Yasojima, K. Articles by McGeer, P. L. Pubmed/NCBI databases Substance via MeSH Related Collections Pathophysiology Gene expression Mechanism of atherosclerosis/growth factors

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1214.)
© 2001 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Complement Components, but Not Complement Inhibitors, Are Upregulated in Atherosclerotic Plaques

K. Yasojima; C. Schwab; E. G. McGeer; P. L. McGeer

From the Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, Vancouver.

Correspondence to Dr Patrick L. McGeer, Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, BC V6T 1Z3. E-mail mcgeerpl{at}interchange.ubc.ca

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Complement activation occurs in atherosclerotic plaques. The capacity of arterial tissue to inhibit this activation through generation of the complement regulators C1 inhibitor, decay accelerating factor, membrane cofactor protein (CD46), C4 binding protein (C4BP), and protectin (CD59) was evaluated in pairs of aortic atherosclerotic plaques and nearby normal artery from 11 human postmortem specimens. All 22 samples produced mRNAs for each of these proteins. The ratios of plaque versus normal artery pairs was not significantly different from unity for any of these inhibitors. However, in plaques, the mRNAs for C1r and C1s, the substrates for the C1 inhibitor, were increased 2.35- and 4.96-fold, respectively, compared with normal artery; mRNA for C4, the target for C4BP, was elevated l.34-fold; and mRNAs for C7 and C8, the targets for CD59, were elevated 2.61- and 3.25-fold, respectively. By Western blotting and immunohistochemistry, fraction Bb of factor B, a marker of alternative pathway activation, was barely detectable in plaque and normal arterial tissue. These data indicate that it is primarily the classical, not the alternative pathway, that is activated in plaques and that key inhibitors are not upregulated to defend against this activation.

Key Words: CD59 • CD46 • C4 binding protein • classical pathway • inflammation

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
It has long been known that there is full activation of the complement cascade in atherosclerotic plaques. The membrane attack complex (MAC) is generated, which could result from activation of either the classical or the alternative pathway, or both.^{1 2 3 4} Association of the MAC with damaged plaque tissue has pointed to the autodestructive nature of this phenomenon. Several theories based on antigen-antibody interactions have been advanced to account for the complement activation. Infectious agents, such as herpesvirus, cytomegalovirus, or Chlamydia pneumoniae, have been proposed as antigenic stimulants,^{5 6 7 8} but it is not clear how this would result in selective opsonization of fibrous plaque tissue. It has also been proposed that antibody-independent mechanisms activate complement, including cholesterol and oxysterols,⁹ which activate the alternative pathway, and C-reactive protein (CRP), which activates the classical pathway.¹⁰ CRP is an attractive candidate because it colocalizes with the MAC in atherosclerotic lesions^{10 11} and is known to activate complement in vitro¹² as well as in vivo.¹³ The reason for CRP localization in plaques has been unclear because it was generally believed to be an acute-phase reactant made exclusively in the liver.¹⁴ However, we have reported that human arterial tissue is capable of generating CRP along with proteins of the classical complement pathway.¹¹ There is upregulation of all these components in atherosclerotic plaques. Colocalization of CRP and C4 mRNAs and the C5b-9 protein complex occurs on transformed cells of the thickened intima, indicating that transformed cells within the plaques may be responsible for the autodestructive damage.

There are many regulators that are designed to control unwanted complement activation. These include C1 inhibitor (C1-INH), C4 binding protein (C4BP), decay accelerating factor (DAF), membrane cofactor protein (MCP, CD46), and protectin (CD59).¹⁵ C1-INH arrests the complement cascade at the stage at which C1q binds to a target, causing dissociation of the C1 complex. It is a suicide inhibitor that attaches covalently to the exposed esterase sites of C1r and C1s. C4BP inhibits C3 convertase by binding to the active fragment C4b. DAF is a glycosylphosphatidylinositol –linked surface protein that accelerates the decay of C4b2a. MCP accelerates cleavage of C3b, primarily in the alternative pathway,¹⁶ but it may also have inhibitory activity in the classical pathway.¹⁷ CD59 is another glycoprotein I–linked cell surface protein that binds to the C7 and C8 components of the MAC as it assembles on the surface of host cells. Thus, it prevents C9 attachment and full insertion of the MAC into the membrane. It is also known as protectin because it protects host cells against bystander lysis.¹⁸ In the present study, we describe the production of all of these inhibitors by normal artery and plaque tissue. We compare their upregulation in plaques with that of their main complement protein targets to assess their ability to defend against the self-damaging effects of complement activation.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Eleven pairs of atherosclerotic plaque tissue and nearby normal arterial tissue were obtained from the aorta of 11 separate postmortem cases. There were multiple causes of death, including various types of malignancy, but none was the result of an acute thrombosis. Tissues were obtained through the Pathology Service of the University of British Columbia Hospital under conditions approved by the University Human Ethics Committee. Postmortem delay varied from 7 to 96 hours, but the variation was not a factor in the results. As we^{19 20} and others^{21 22} have reported, mRNAs are remarkably stable in cooled tissue after death. Total RNA and proteins were extracted from the samples, and portions were taken for immunohistochemical analysis. Levels of the mRNAs for the inhibitors and their substrate complement proteins were subsequently measured. Western blotting of the proteins and immunohistochemical analysis for C1-INH, CD59, and fraction Bb of factor B were also carried out.

The techniques used for RNA extraction and preparation of reverse transcription (RT)–polymerase chain reaction (PCR) products, as well as for protein extraction, Western blotting, and immunohistochemistry, were as previously reported in detail.^{11 18 19 23}

Briefly, total RNA was extracted from 500 mg of tissue samples by the acid guanidinium thiocyanate–phenol–chloroform method. Single-strand cDNA synthesis was performed on 5-µg samples of total RNA extract. The resultant cDNAs (1-µL aliquots) were amplified by using appropriate primers and standard buffer. The primers used, along with GenBank accession numbers and the endonucleases used for identifying the RT-PCR products, are shown in Table 1. The thermal profile consisted of a denaturation step of 94°C for 1 minute, an annealing step of 30 seconds at 61°C for C1-INH, 56°C for DAF, 60°C for C4BP and MCP, and 57°C for CD59, and an extension step of 72°C for 1 minute, except for 3 minutes in the first cycle. All samples were initially denatured for a total of 9 minutes (94°C). Preliminary experiments were carried out with each set of primers to determine the range of cDNA concentration and PCR cycle amplification number that would give reliable comparative values for each cDNA product. Cyclophilin mRNA was chosen as the internal standard because of the consistency of its level from tissue to tissue and its postmortem stability. A linear relationship was found between the log of PCR product intensity and cycle number of cyclophilin (between 20 and 29 cycles), C1-INH and CD59 (between 24 and 30 cycles), DAF (between 27 and 33 cycles), C4BP (between 27 and 37 cycles), MCP (between 29 and 33 cycles), and complement components (between 25 and 37 cycles), after which plateaus were reached. A linear relationship was found between the amount of cDNA product obtained and the original cDNA added within the range corresponding to 0.01 to 0.5 µg total RNA. Accordingly, standard conditions were followed in which cDNA (1 µL) corresponding to 0.1 µg total RNA was added, and the cyclophilin product was amplified for 27 cycles. In parallel experiments, the C1-INH and CD59 products were amplified for 29 cycles; the DAF, C4BP, and MCP products, for 30 cycles; and the complement products, for 35 cycles.

View this table: [in this window] [in a new window]   Table 1. Primer Sequences Used, Restriction Enzymes, and Product Fragment Lengths

Each PCR reaction product was electrophoresed through a 6% polyacrylamide gel, and the product was visualized by incubation for 10 minutes in a solution containing 10 ng/mL ethidium bromide. Resulting gel bands were imaged by using a GDS 7600 image analyzer (Ultra Violet Product). The relative intensities of the bands, expressed as optical density units, were quantitatively analyzed by using NIH image software 1.62. Each mRNA analysis was made in parallel with a cyclophilin mRNA analysis to provide an internal standard. Values normalized to cyclophilin, as well as uncorrected data, were analyzed. Cyclophilin values were almost constant from sample to sample. Most were within 1% of each other, with the range <4%, so that the normalization corrections were very small. Polaroid photographs of the gels were taken. The PCR products were of the expected size, and endonuclease digestion in each case gave fragments of the predicted size as previously reported.^{11 18 19} In all experiments, the presence of possible contaminants was checked by control reactions in which amplification was carried out for up to 40 cycles on samples in which we omitted from the RT-PCR reaction mixture either (1) the reverse transcriptase or (2) a template cDNA. No product was obtained under these conditions.

Western blots were performed on extracts of the soluble fraction of homogenates of normal or plaque tissue as previously described.¹¹ Briefly, tissue samples were homogenized in 5 times (vol/wt) extraction buffer (0.02 mol/L Tris-HCl, pH 7.5, and 0.1% Triton X) containing the protease inhibitors phenylmethylsulfonyl fluoride (10 µg/mL) and aprotinin (10 µg/mL) and 1 mmol/L EDTA. Homogenates were centrifuged at 18 000g at 4°C for 30 minutes. The protein content of the supernatants was determined by Lowry’s method. The samples were diluted in SDS sample buffer (60 mmol/L Tris, pH 6.8, 2.5% SDS, and 5% 2-mercaptoethanol) to a final protein content of 5 mg/mL and were boiled for 3 minutes. Samples containing 70 µg of protein were loaded onto 7.5% polyacrylamide minigels. Life Technologies high-range prestained standards were used as molecular weight markers. The separated proteins were transferred onto nitrocellulose membranes, stained with Ponceau staining solution (Sigma), and scanned densitometrically. Membranes were blocked in 5% skim milk for 6 hours. The immunoblots were next treated for 6 hours at room temperature with a primary antibody, followed by treatment for 2 hours with a secondary antibody labeled with horseradish peroxidase. Immunoreactivity was visualized by incubation with Supersignal CL-HRP chemiluminescent substrate (Pierce Chemical Co). After draining, the membranes were covered in clear plastic wrapping and exposed to x-ray film (Hyper film ECL, Amersham Life Science) for 0.3 to 2 minutes, depending on the strength of the signal. Protein loading differences were corrected for by densitometric quantification of Ponceau staining. The primary antibodies were goat anti–C1-INH (Quidel, 1: 3000), rat anti-CD59 (Serotec, 1:500), goat anti-C1r (ICN, 1:2000), goat anti-C1s (Quidel, 1:2500), rabbit anti-C4BP (Calbiochem, 1:2000), goat anti-C4 (Chemicon, 1:10 000), mouse anti-C4d (Quidel, 1:5000), goat anti-C7 (Quidel, 1:3000), goat anti-C8 (Calbiochem, 1:5000), and mouse monoclonal anti–fraction Bb (Quidel, 1:500). All secondary antibodies were from Sigma (1:8000).

Immunohistochemistry was carried out on paraffin-embedded tissue, as previously described,^{24 25} with the same antibodies used for Western blotting. Sections were cut at 10 mm, deparaffinized in toluene, and processed in the free-floating state. The C1-INH antibody was used at a concentration of 1:15 000, and the CD59 and fraction Bb antibodies were used at a concentration of 1:500. Secondary antibodies were from Vector (1:1000), as was the avidin-biotinylated horseradish peroxidase (Vector ABC-Elite) labeling reagent. Color was developed with 0.01% diaminobenzidine (Sigma) enhanced with nickel ammonium sulfate.

The data on relative levels of the mRNAs were first analyzed by ANOVAs, with subsequent Student t tests being used to determine the probability value for differences between plaque and normal tissue. The plaque/normal tissue ratio was calculated for each pair and analyzed by ANOVA, followed by Student t tests for the difference from 1. The probability values were corrected by the method of Holm²⁶ for multiple assays.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Ethidium bromide–stained gels of RT-PCR products are shown in Figure 1. Each of the 11 lanes compares a normal aortic segment with a companion plaque. Overall, they illustrate that no detectable enhancement of the regulators C1-INH, DAF, C4BP, MCP, and CD59 occurs in plaque compared with paired normal arterial tissue but that significant upregulation of the target complement mRNAs C1r, C1s, C4, C7, and C8 does take place in plaques.

View larger version (120K): [in this window] [in a new window]   Figure 1. Polaroid photographs of ethidium bromide–stained gels of electrophoresed RT-PCR products for C1-INH, C1r, C1s, DAF, C4BP, CD46, CD59, C7, and C8. Lanes 1 to 11 are paired samples from the 11 postmortem cases with normal artery (N) and plaque (P) representing the pairs. Size markers are in lane M, with the size of the RT-PCR products indicated by the arrows on the right. Notice the constant intensity bands for C1-INH, DAF, C4BP, CD46, and CD59 in normal and plaque tissue. In contrast, C1r, C1s, C7,and C8 all show a considerably stronger band in each plaque compared with the normal arterial pair.

Table 2 gives quantitative values for the mRNAs. The housekeeping gene cyclophilin was almost constant for all tissues, indicating the stability of the mRNAs. Moreover, the values for normal tissue from case to case and for plaques from case to case varied little for any of the other mRNAs. This indicates that such confounding factors, such as cause of death and postmortem delay, are not significant contributors to the values under study.

View this table: [in this window] [in a new window]   Table 2. Levels of mRNAs in Paired Normal and Atheromatous Aortic Tissue for C1-INH, DAF, C4BP, MCP, CD59, and the Complement Proteins With Which They Interact

Table 2 also gives the average ratio of plaque to normal artery mRNA levels for the 11 matched pairs. For the regulators, they were as follows: C1-INH 1.04, C4BP 0.97, MCP 0.94, and CD59 1.06. None of these ratios was significantly different from 1. However, C1r, C1s, C4, C7, and C8 all showed significant increases (P<0.001), with ratios of 2.35, 4.96, 1.34, 2.61, and 3.25, respectively.

Figure 2 shows typical Western blots comparing protein extracts from a normal artery and a paired nearby plaque. This is illustrated for C1-INH compared with its 2 substrates C1r and C1s, C4BP compared with C4 and C4d, and CD59 compared with C7 and C8. Figure 2 also compares Western blots of fraction Bb of factor B in normal human serum compared with the same serum activated by IgG, a normal artery, and a nearby plaque. The figure illustrates that no discernible differences between normal arterial and plaque tissue can be seen for the regulators C1-INH, C4BP, CD59, and fraction Bb, with the last being a specific marker of alternative pathway activation. In contrast, compared with its companion normal artery, plaque tissue shows strong upregulation for C1r and C1s, for C4 and C4d, and for C7 and C8. C4d is a specific marker of classical pathway activation. These results are consistent with the mRNA data of Table 2. Additionally, serum activated by IgG, but not normal serum, gave a strong band for fraction Bb, indicating that aggregated IgG, when added to serum, will activate the alternative pathway and that no apparent activation of the alternative pathway is occurring in plaque tissue.

View larger version (46K): [in this window] [in a new window]   Figure 2. Typical Western blot results on protein extracts of normal (N) vs plaque (P) tissue and normal vs IgG-activated serum. Size markers are shown on the right, and arrows on the left indicate the location of the protein bands. Top row, C1-INH compared with C1r and C1s. It can be seen that C1-INH gave single bands of 100 kDa and that C1r and C1s gave bands of 85 kDa, consistent with previously reported values. The bands for C1-INH appear to be of equal strength in plaque compared with normal artery, but considerably stronger bands for C1r and C1s can be seen in the plaque samples. The comparative strength in plaque vs normal artery is noticeably greater for C1s than C1r. Notice also a faint minor band for C1s. Second row, C4BP compared with C4 and C4d. Bands of 70 kDa, corresponding to the reported molecular weight of C4BP, were detected in normal artery and plaque tissue. They were relatively equal in intensity. In contrast, a much stronger band for C4 of 75 kDa was obtained in plaque compared with normal artery. A clearly detectable band for C4d, a specific marker of classical pathway activation, of 45 kDa was obtained from plaque tissue, but no detectable band was obtained from normal artery. Third row, CD59 compared with C7 and C8. Bands of 18 kDa for CD59, 115 kDa for C7, and 85 kDa for C8 can be seen, which is consistent with previously reported values. The bands for CD59 appear to be of comparable strength in normal and plaque tissue. Only faint bands (indicated by arrowheads) can be visualized in normal artery for C7 and C8, whereas strong bands can be seen in plaque tissue. C8 shows a stronger main band than does C7, and a faint secondary band is also visible. Bottom row, Comparison of fraction Bb expression in normal serum (NS) diluted 1:20, the same serum activated (AS) for 1 hour at 37°C with heat-aggregated IgG (see detailed methodology20 ), normal artery, and plaque tissue. A prominent band of 63 kDa, corresponding to the reported molecular weight of fraction Bb, was obtained in activated human serum, but only barely detectable bands of equal intensity were obtained from normal artery and plaque tissue.

Figure 3 illustrates immunohistochemical results for C1-INH, CD59, and fraction Bb staining. Overall, they show a similar intensity of staining in plaque compared with normal artery for both C1-INH and CD59, although the staining in plaque tissue is more widespread. The distribution is somewhat different. C1-INH staining is more prominent in the intimal and adventitial layers than in the medial layer (Figure 3A). In plaque tissue, C1-INH staining is widespread in the proliferating fibrous zone and appears to be intracellular and extracellular (Figure 3B). CD59 staining is intense in the endothelial layer, as previously described²⁷ (Figures 3C and 3D), with weaker staining in the other layers. In fibrous plaque tissue, the antibody to CD59 weakly stains some elongated fibromyocytes and some round cells resembling leukocytes (Figure 3D). Overall, the immunohistochemical findings for C1-INH and CD59 are consistent with the mRNA and Western blot data, showing a failure to upregulate the inhibitors in inflamed plaque tissue. Fraction Bb staining was very faint (Figure 3E), with no structures being identifiable.

View larger version (129K): [in this window] [in a new window]   Figure 3. Immunostaining of a normal artery (A and C) and a nearby plaque (B and D) for C1-INH (A and B) and CD59 (C and D). Lumen is at the top. Panel E shows immunostaining for fraction Bb of a cross section with a normal area indicated by the arrow and a plaque indicated by an asterisk. See Methods for details. In the normal artery (A), C1-INH staining was most intense in the endothelial layer. It was prominent in the intima and adventitia but very weak in the media. Immunoreactivity seemed to occur both extracellularly and intracellularly. In the plaque (B), immunostaining for C1-INH covered a larger area but was of similar intensity to normal artery. The intima, which is considerably thickened and peeled away from the media, showed moderate staining, whereas immunoreactivity in the media was very weak. CD59 immunoreactivity followed a similar pattern but was less intense than that of C1-INH. In normal artery (C), CD59 immunoreactivity was very strong over the endothelial layer and was visible in the intima and adventitia, whereas the media was nearly unstained. In plaque tissue (D), a similar pattern was seen, although the intimal layer was greatly thickened. Staining was often weakly associated with elongated cells. Additionally and in the diseased tissue only, some cells of probable leukocytic origin were stained moderately by the CD59 antibody. Bars=100 µm in panel C (for panels A and C) and 180 µm in panel D (for panels B and D). In panel E, only trace immunoreactivity was observed for fraction Bb, with no detectable difference between the region of normal arterial wall (arrow) and a prominent fibrous plaque (asterisk). Bar=200 µm.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The data described in the present study show that normal arterial cells produce the key complement regulators C1-INH, DAF, C4BP, MCP, and CD59. This is consistent with a previous study,²⁸ which reported that rat arterial smooth muscle cells produce DAF, MCP, and CD59 as well as the complement proteins C3, C4, and C5. The regulator levels are not significantly increased in plaque tissue, but the complement proteins that they regulate are significantly enhanced.¹¹ Thus, these regulatory mechanisms are unable to defend the host against complement activation within the plaque. There is full activation of the classical complement pathway in plaque tissue,¹¹ and localization of the autolytic MAC on damaged transformed myocytes emphasizes the harmful aspects of this activation. In contrast, the failure to identify more than trace amounts of fraction Bb of factor B, a specific marker for activation of the alternative pathway,²⁹ in either normal artery or nearby plaque tissue would suggest that activation of the alternative pathway is not a significant factor.

We have previously shown that all components of the classical complement pathway are produced within arterial tissue and that they are all significantly upregulated in plaques.¹¹ Moreover, we have shown that CRP, a known complement activator, is also produced by arterial tissue and is more upregulated than any of the complement proteins. Thus, the mechanism for a self-sustaining complement attack generated within plaque tissue itself is clearly present.

In several previous publications, it has been shown that CRP and the MAC colocalize on damaged cells in the proliferating zone of plaque tissue.^{4 10 11} The fact that the relevant mRNAs are also colocalized to these same cells indicates that the process is internal to plaque tissue. Although the plaque deposits build up over time and are, thus, the end result of a long-standing pathological process, the half-life of mRNAs is usually minutes to hours. Therefore, the mRNA levels give a dynamic picture of what is continuously occurring in plaque tissue.

The reason for the proliferation of cells in the deep intimal layers of evolving plaque tissue is unclear. It is proposed that oxidized LDL is a stimulant for such proliferation.³⁰ This may be an initial stimulus, but it is possible that continuing complement attack is also acting as a stimulus, thus enhancing the plaque enlargement process. Macrophage attack occurs on opsonized targets, and such an attack is easily discerned within the proliferating plaque shoulder area. The process leads to 2 unfortunate outcomes. The first is dissolution of the fibrous coat by macrophage collagenase activity, releasing material that causes platelet aggregation and thrombotic activity.³¹ The second is continued growth of the plaque, resulting in arterial stenosis.

The inflammatory reaction within plaques is somewhat analogous to the situation in Alzheimer brain tissue. Amyloid deposits stimulate macrophages, which provide a stressful environment for neurons. The neurons produce upregulated levels of CRP³² and all of the complement proteins.²⁴ However, they do not produce upregulated levels of C1-INH and CD59,¹⁸ and fraction Bb is not detected.²³ The consequence is full activation of the classical complement pathway. Extracellular deposits are opsonized, but the MAC localizes on damaged neurites, providing evidence of autodestruction.²⁴ However, unlike myocytes, neurons cannot proliferate, so loss of vital tissue occurs rather than an expansion of unwanted tissue.

The reaction in plaques is also somewhat analogous to the situation in infarcted myocardium. Heart tissue is also capable of synthesizing all of the complement proteins, and there is substantial upregulation, coupled with complement activation in infarcted areas.²⁰ The MAC is observed attacking damaged myocardial fibers, not only in acutely infarcted areas³³ but also in the region of old infarcts.²⁰ CRP colocalizes with the MAC in infarcted tissue.³⁴

Other activators of the classical complement pathway may be involved. These include mannan-binding protein, an activator of the closely related lectin pathway,^{35 36} enzymatically modified LDL,³⁷ and even IgG. But these are all inhibited, including the lectin pathway,^{35 36} by the regulators described in the present study. Of course, there may be other less specific inhibitors, such as ₂-macroglobulin and ₁-antitrypsin, which play a role in inhibiting the complement cascade, but it cannot be a decisive role because robust activation is clearly taking place in plaque tissue.

In summary, the data reported in the present study suggest that complement activation is at the core of the inflammatory process that characterizes atherosclerosis. The inflammation is silent because arteries lack pain fibers. Therapeutic intervention to reduce the inflammatory process may be an effective addition to reducing the levels of cholesterol and other lipids. Once the inflammatory process in a plaque is initiated, arrest may not be achieved by simple lowering of circulating lipid levels. Controlling the autodestructive local process by inhibiting complement activation may be essential.

	Acknowledgments

 
This research was supported by a grant from the Jack Brown and Family A.D. Research Fund as well as donations from individual British Columbians. We thank Dr Blake Gilks of the Pathology Department of the University of British Columbia for helpful discussions and assistance in obtaining tissue.

Received April 11, 2001; accepted April 25, 2001.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Niculescu F, Rus H, Cristea A, Vlaicu R. Localization of the terminal C5b-9 complement complex in the human aortic atherosclerotic wall. Immunol Lett. 1985;10:109–114.[Medline] [Order article via Infotrieve]

2. Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis. 1987;65:1–11.[Medline] [Order article via Infotrieve]

3. Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis. 1985;57:163–177.[Medline] [Order article via Infotrieve]

4. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, Gabbert HE, Bhakdi S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol. 1998;18:369–378.[Abstract/Free Full Text]

5. Libby P, Egan D, Skarkatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 1997;96:4095–4103.[Free Full Text]

6. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol. 1990;136:23–28.[Abstract]

7. Jackson LA, Campbell LA, Schmidt JT, Kuo CC, Cappuccio AL, Lee MJ, Grayston JT. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol. 1997;150:1785–1790.[Abstract]

8. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J. 1993;14(suppl K):30–38.

9. Seifert PS, Kazarchkine MD. The complement system in atherosclerosis. Atherosclerosis. 1988;73:91–104.[Medline] [Order article via Infotrieve]

10. Torzewski J, Torzewski M, Bowyer DE, Frohlich M, Koenig W, Waltenberger J, Fitzsimmons C, Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386–1392.[Abstract/Free Full Text]

11. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039–1057.[Abstract/Free Full Text]

12. Siegel J, Rent R, Gewurz H. Interactions of C-reactive protein with the complement system. J Exp Med. 1974;140:631–637.[Abstract]

13. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo. J Immunol. 1996;157:473–479.[Abstract]

14. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454.[Free Full Text]

15. Morgan EP. Physiology and pathophysiology of complement progress and trends. Clin Rev Clin Lab Sci. 1995;32:265–298.

16. Devaux P, Christiansen D, Fontaine M, Gerlier D. Control of C3b and C5b deposited by CD46 (membrane cofactor protein) after alternative but not classical complement activation. Eur J Immunol. 1999;29:815–822.[Medline] [Order article via Infotrieve]

17. Liszewski MK, Atkinson JP. Membrane cofactor protein (MCP CD46): isoforms differ in protection against the classical pathway of complement. J Immunol. 1996;156:4415–4421.[Abstract]

18. Yasojima K, McGeer EG, McGeer PL. Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. Brain Res. 1999;833:297–301.[Medline] [Order article via Infotrieve]

19. Yasojima K, Schwab C, McGeer EG, McGeer PL. Upregulated production and activation of the complement system in Alzheimer’s disease brain. Am J Pathol. 1999;154:927–936.[Abstract/Free Full Text]

20. Yasojima K, Schwab C, McGeer EG, McGeer PL. Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res. 1998;83:860–869.[Abstract/Free Full Text]

21. Johnson SA, Morgan DG, Finch CE. Extensive postmortem stability of RNA from rat and human brain. J Neurosci Res. 1986;16:267–280.[Medline] [Order article via Infotrieve]

22. Morrison MR, Griffin WST. The isolation and in vitro translation of undegraded messenger RNAs from human postmortem brain. Anal Biochem. 1981;113:318–324.[Medline] [Order article via Infotrieve]

23. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer’s disease. Can J Neurol Sci. 1989;16:516–527.[Medline] [Order article via Infotrieve]

24. Walker DG, Yasuhara O, Patston PA, McGeer EG, McGeer PL. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 1995;675:75–82.[Medline] [Order article via Infotrieve]

25. McGeer PL, Walker DG, Akiyama H, Kawamata T, Guan AL, Parker CJ. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res. 1991;544:315–319.[Medline] [Order article via Infotrieve]

26. Holm S. A simple sequentially repetitive multiple test procedure. Scand J Statist.. 1979;6:65–70.

27. Seifert PS, Roth I, Schmiedt W, Oelert H, Okada N, Okada H, Bhakdi S. CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. Atherosclerosis. 1992;96:135–145.[Medline] [Order article via Infotrieve]

28. Li W, Tada T, Miwa T, Okada N, Ito J, Okada H, Tateyama H, Eimoto T. mRNA expression of complement proteins and regulators in rat smooth muscle cells. Microbiol Immunol. 1999;43:585–593.[Medline] [Order article via Infotrieve]

29. Kolb WP, Morrow PR, Tamerius JD. Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples. Complement Inflamm. 1989;6:175–204.[Medline] [Order article via Infotrieve]

30. Zettler ME, Pierce GN. Growth-promoting effects of oxidized low density lipoprotein. Can J Cardiol. 2001;17:73–79.[Medline] [Order article via Infotrieve]

31. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126.[Free Full Text]

32. Yasojima K, Schwab C, McGeer EG, McGeer PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res. 2000;887:80–89.[Medline] [Order article via Infotrieve]

33. Schafer H, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5b-9 complex in infarcted areas of human myocardium. J Immunol. 1986;137:1945–1949.[Abstract]

34. Lagrand WK, Niessen HWM, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FWA, Meijer CJLM, Hack CE. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation. 1997;95:97–103.[Abstract/Free Full Text]

35. Suankratay C, Mold C, Zhang Y, Lint TF, Gewurz H. Mechanism of complement-dependent hemolysis via the lectin pathway: role of the complement regulatory proteins. Clin Exp Immunol. 1999;117:442–448.[Medline] [Order article via Infotrieve]

36. Gadjeva M, Thiel S, Jensenius JC. The mannan-binding-lectin pathway of the innate immune response. Curr Opin Immunol. 2001;13:74–78.[Medline] [Order article via Infotrieve]

37. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, Gabbert HE, Bhakdi S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol. 1998;18:369–378.

This article has been cited by other articles:

				V. W.Y. Leung, S. Yun, M. Botto, J. C. Mason, T. H. Malik, W. Song, D. Paixao-Cavalcante, M. C. Pickering, J. J. Boyle, and D. O. Haskard Decay-Accelerating Factor Suppresses Complement C3 Activation and Retards Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice Am. J. Pathol., October 1, 2009; 175(4): 1757 - 1767. [Abstract] [Full Text] [PDF]

				R. A. Matthijsen, M. P.J. de Winther, D. Kuipers, I. van der Made, C. Weber, M. V. Herias, M. J.J. Gijbels, and W. A. Buurman Macrophage-Specific Expression of Mannose-Binding Lectin Controls Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice Circulation, April 28, 2009; 119(16): 2188 - 2195. [Abstract] [Full Text] [PDF]

				E. Shagdarsuren, K. Bidzhekov, Y. Djalali-Talab, E. A. Liehn, M. Hristov, R. A. Matthijsen, W. A. Buurman, A. Zernecke, and C. Weber C1-Esterase Inhibitor Protects Against Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice Circulation, January 1, 2008; 117(1): 70 - 78. [Abstract] [Full Text] [PDF]

				F. Verdeguer, C. Castro, M. Kubicek, D. Pla, M. Vila-Caballer, A. Vinue, F. Civeira, M. Pocovi, J. J. Calvete, and V. Andres Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation Cardiovasc Res, November 1, 2007; 76(2): 340 - 350. [Abstract] [Full Text] [PDF]

				D. R. Anderson, J. M. Tsutsui, F. Xie, S. J. Radio, and T. R. Porter The role of complement in the adherence of microbubbles to dysfunctional arterial endothelium and atherosclerotic plaque Cardiovasc Res, February 1, 2007; 73(3): 597 - 606. [Abstract] [Full Text] [PDF]

				M.-L. Gross, H.-P. Meyer, H. Ziebart, P. Rieger, U. Wenzel, K. Amann, I. Berger, M. Adamczak, P. Schirmacher, and E. Ritz Calcification of Coronary Intima and Media: Immunohistochemistry, Backscatter Imaging, and X-Ray Analysis in Renal and Nonrenal Patients Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 121 - 134. [Abstract] [Full Text] [PDF]

				K. C. Kregel and H. J. Zhang An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R18 - R36. [Abstract] [Full Text] [PDF]

				A. M Carter Inflammation, thrombosis and acute coronary syndromes Diabetes and Vascular Disease Research, October 1, 2005; 2(3): 113 - 121. [Abstract] [PDF]

				L. Persson, J. Boren, A.-K. L. Robertson, V. Wallenius, G. K. Hansson, and M. Pekna Lack of Complement Factor C3, but Not Factor B, Increases Hyperlipidemia and Atherosclerosis in Apolipoprotein E-/- Low-Density Lipoprotein Receptor-/- Mice Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1062 - 1067. [Abstract] [Full Text] [PDF]

				S.-H. Li, P. E. Szmitko, R. D. Weisel, C.-H. Wang, P. W.M. Fedak, R.-K. Li, D. A.G. Mickle, and S. Verma C-Reactive Protein Upregulates Complement-Inhibitory Factors in Endothelial Cells Circulation, February 24, 2004; 109(7): 833 - 836. [Abstract] [Full Text] [PDF]

				A. Paul, K. W.S. Ko, L. Li, V. Yechoor, M. A. McCrory, A. J. Szalai, and L. Chan C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, February 10, 2004; 109(5): 647 - 655. [Abstract] [Full Text] [PDF]

				R. Oksjoki, H. Jarva, P. T. Kovanen, P. Laine, S. Meri, and M. O. Pentikainen Association Between Complement Factor H and Proteoglycans in Early Human Coronary Atherosclerotic Lesions: Implications for Local Regulation of Complement Activation Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 630 - 636. [Abstract] [Full Text] [PDF]

				J. C. Mason, Z. Ahmed, R. Mankoff, E. A. Lidington, S. Ahmad, V. Bhatia, A. Kinderlerer, A. M. Randi, and D. O. Haskard Statin-Induced Expression of Decay-Accelerating Factor Protects Vascular Endothelium Against Complement-Mediated Injury Circ. Res., October 18, 2002; 91(8): 696 - 703. [Abstract] [Full Text] [PDF]

				J. Wojta, C. Kaun, G. Zorn, M. Ghannadan, A. W. Hauswirth, W. R. Sperr, G. Fritsch, D. Printz, B. R. Binder, G. Schatzl, et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils Blood, June 28, 2002; 100(2): 517 - 523. [Abstract] [Full Text] [PDF]

				C. Buono, C. E. Come, J. L. Witztum, G. F. Maguire, P. W. Connelly, M. Carroll, and A. H. Lichtman Influence of C3 Deficiency on Atherosclerosis Circulation, June 25, 2002; 105(25): 3025 - 3031. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yasojima, K. Articles by McGeer, P. L. Search for Related Content PubMed PubMed Citation Articles by Yasojima, K. Articles by McGeer, P. L. Pubmed/NCBI databases Substance via MeSH Related Collections Pathophysiology Gene expression Mechanism of atherosclerosis/growth factors